AIM ImmunoTech Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat AIM ImmunoTech de winst en omzet met respectievelijk 2.7% en 70.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 6.7% per jaar.

Belangrijke informatie

2.7%

Groei van de winst

6.7%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	70.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	21 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NYSEAM:AIM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	4	-16	N/A	N/A	2
12/31/2025	2	-16	N/A	-6	3
12/31/2024	0	-18	N/A	-8	3
9/30/2024	0	-24	-21	-21	N/A
6/30/2024	0	-28	-24	-23	N/A
3/31/2024	0	-31	-23	-22	N/A
12/31/2023	0	-29	-22	-21	N/A
9/30/2023	0	-21	-18	-18	N/A
6/30/2023	0	-19	-17	-17	N/A
3/31/2023	0	-19	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-21	-16	-16	N/A
6/30/2022	0	-18	-15	-14	N/A
3/31/2022	0	-19	-14	-14	N/A
12/31/2021	0	-19	-15	-14	N/A
9/30/2021	0	-17	-12	-11	N/A
6/30/2021	0	-17	-11	-11	N/A
3/31/2021	0	-14	-11	-10	N/A
12/31/2020	0	-14	-11	-10	N/A
9/30/2020	0	-12	-10	-10	N/A
6/30/2020	0	-11	-10	-9	N/A
3/31/2020	0	-10	-11	-11	N/A
12/31/2019	0	-9	-9	-9	N/A
9/30/2019	0	-10	-9	-9	N/A
6/30/2019	0	-10	-10	-10	N/A
3/31/2019	0	-10	-10	-10	N/A
12/31/2018	0	-10	-11	-11	N/A
9/30/2018	0	-10	-9	-9	N/A
6/30/2018	0	-8	N/A	-8	N/A
3/31/2018	0	-8	N/A	-7	N/A
12/31/2017	0	-8	N/A	-8	N/A
9/30/2017	0	-7	N/A	-9	N/A
6/30/2017	0	-9	N/A	-10	N/A
3/31/2017	0	-8	N/A	-9	N/A
12/31/2016	0	-8	N/A	-7	N/A
9/30/2016	0	-9	N/A	-9	N/A
6/30/2016	0	-10	N/A	-9	N/A
3/31/2016	0	-14	N/A	-13	N/A
12/31/2015	0	-15	N/A	-16	N/A
9/30/2015	0	-17	N/A	-17	N/A
6/30/2015	0	-17	N/A	-17	N/A
3/31/2015	0	-17	N/A	-15	N/A
12/31/2014	0	-17	N/A	-14	N/A
9/30/2014	0	-16	N/A	-13	N/A
6/30/2014	0	-17	N/A	-13	N/A
3/31/2014	0	-16	N/A	-14	N/A
12/31/2013	0	-16	N/A	-17	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat AIM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat AIM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat AIM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van AIM ( 70.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van AIM ( 70.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van AIM naar verwachting over 3 jaar hoog zal zijn

AIM ImmunoTech Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 19% to US$4.25

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 52%

Price target decreased by 30% to US$2.75

Consensus EPS estimates fall by 12%

Consensus revenue estimates increase by 15%

Recent updates

New major risk - Financial position

Kellner Group Urges Immediate Change at AIM Immunotech Inc

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

Price target increased by 19% to US$4.25

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

Consensus EPS estimates fall by 15%

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023)

Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board

AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

Consensus revenue estimates increase by 52%

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023)

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

Price target decreased by 30% to US$2.75

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Consensus revenue estimates increase by 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Price target decreased by 7.8% to US$4.92

Price target decreased by 7.7% to US$5.00

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

Consensus revenue estimates decrease by 83%, EPS upgraded

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

Executive Vice Chairman recently bought US$50k worth of stock

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Consensus revenue estimates fall by 34%

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

Consensus revenue estimates fall by 23%

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

Consensus forecasts updated